EUCTR2017-001582-25-SE进行中（未招募）1 期
A 4-week, randomized, single-blind, placebo-controlled, multi-centre, parallel group, phase IIa study to evaluate efficacy, safety and tolerability of oral AZD5718 in patients with coronary artery disease (CAD) - FLAVOUR
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For inclusion in the study patients should fulfil the following criteria:
- •1.Males and females:
- •a.Males must be surgically sterile or using an acceptable method of contraception
- •b.Females must be of non-childbearing potential confirmed at screening by fulfilling one of the following criteria a) postmenopausal defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle-stimulating hormone (FSH) levels in the postmenopausal range, b) documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation
- •2.Age =18 to =75
- •3.BMI =18 to =35 kg/m2
- •4.CAD patients, here defined as:
- •a.ACS 7-28 days prior to study randomization (ACS defined as STEMI, non STEMI event documented by ECG, cardiac enzymes [troponin] and angiogram)
- •b.Possible post procedure LAD stenosis is <50% and TIMI flow is = 2
- •5.Provision of signed and dated, written informed consent prior to any study specific procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •Patients should not enter the study if any of the following exclusion criteria are fulfilled:
- •1Alanine aminotransferase (ALT) >2 x ULN (i.e., above the normal range) at visit 2, cirrhosis, recent hepatitis, or positive screening test for hepatitis B (hepatitis B surface antigen) or hepatitis C
- •2Uncontrolled Type 1 or Type 2 diabetes defined as haemoglobin A1c (HbA1c) Diabetes Control and Complications Trial (DCCT)> 9% or International Federation of Clinical Chemistry (IFCC) >74.9 mmol/mol
- •3Patients with atrial fibrillation (chronic or current) or history of ventricular tachycardia requiring therapy for termination, or symptomatic sustained ventricular tachycardia or sick sinus syndrome or AV blockage degree 2-3
- •4Patients with pacemaker
- •5Prior coronary artery by-pass graft (CABG) to LAD
- •6Left ventricle ejection fraction < 30%
- •7Unacceptable level of angina despite maximal medical therapy or unstable angina at entry Canadian Cardiovascular Society (CCS) = 3 (Visit 1 or Visit 2)
- •8Stroke within the previous 6 months from ACS or ongoing treatment with Persantin or Asasantin
- •9Planned treatment with zileuton, leukotriene receptor antagonists (e.g. montelukast), coumadin or steroids during trial
- •10Planned statin therapy dose regimen changes during trial
- •11Chronic use of anticoagulants on therapeutic dose (not including thrombosis prophylaxis) during the study
- •12Planned additional cardiac intervention (e.g., PCI, CABG) within next 6 months
- •13NYHA class III-IV heart failure at discharge or hospitalization for exacerbation of chronic heart failure within the previous 3 months from ACS
- •14Previously known severe renal disease (CKD stage 4 or 5) or previously known creatinine clearance calculated by Cockcroft Gault equation <30 ml/min*m2
- •15Aortic or mitral valvular disease or valvular disease classified as severe
- •16Known allergy to adenosine
- •17Known elevated intracranial pressure
- •18Heart rate < 40 bpm
- •19Systolic blood pressure < 90 mmHg
- •20Asthma or COPD with strong reactive component in judgment of investigator
- •21Treatment with dipyridamole, theophyllamine, fluvoxamine, rifampicin, fenytoin or carbamazepine
- •22Inability to comply with the study protocol
- •23History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity to drugs with a similar chemical structure or class as study drugs
- •24Patients unable to give their consent or communicate reliably with the investigator or vulnerable patients e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order
- •25Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
- •26Participation in another clinical study with an investigational product during the last 3 months
- •27Previous randomization in the present study
- •28Known history or current abuse of drugs or alcohol
研究者
相似试验
已完成
不适用
A 4 week, double-blind, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of UL-F on allergic rhinitisDiseases of th respiratory systemKCT0002004STR Biotech96
进行中（未招募）
不适用
A placebo controlled trial of of three doses of BCX7353 to evaluate the safety and efficacy in the prevention of attacks in patients with HAEHereditary AngioedemaMedDRA version: 18.1Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-003923-74-HUBioCryst Pharmaceuticals Inc24
进行中（未招募）
1 期
A placebo controlled trial of of three doses of BCX7353 to evaluate the safety and efficacy in the prevention of attacks in patients with HAEMedDRA version: 18.1Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersHereditary AngioedemaEUCTR2015-003923-74-GBBioCryst Pharmaceuticals Inc24
招募中
不适用
The Evaluation of the Efficacy and Safety of NAO on Immune functioKCT0006925Dynebio100
进行中（未招募）
不适用
A 4 week double-blind, placebo-controlled, randomized, parallel group phase IIa study to assess the efficacy and safety of AZD1981 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseChronic Obstructive Pulmonary DiseaseEUCTR2008-000340-13-BGAstraZeneca AB130